Comprehensive molecular characterization of gastric adenocarcinoma
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Gastric cancer is a leading cause of cancer deaths, but analysis of its molecular and clinical characteristics has been complicated by histological and aetiological heterogeneity. Here we describe a comprehensive molecular evaluation of 295 primary gastric adenocarcinomas as part of The Cancer Genome Atlas (TCGA) project. We propose a molecular classification dividing gastric cancer into four subtypes: tumours positive for Epstein–Barr virus, which display recurrent PIK3CA mutations, extreme DNA hypermethylation, and amplification of JAK2, CD274 (also known as PD-L1) and PDCD1LG2 (also known as PD-L2); microsatellite unstable tumours, which show elevated mutation rates, including mutations of genes encoding targetable oncogenic signalling proteins; genomically stable tumours, which are enriched for the diffuse histological variant and mutations of RHOA or fusions involving RHO-family GTPase-activating proteins; and tumours with chromosomal instability, which show marked aneuploidy and focal amplification of receptor tyrosine kinases. Identification of these subtypes provides a roadmap for patient stratification and trials of targeted therapies. The Cancer Genome Atlas reports on molecular evaluation of 295 primary gastric adenocarcinomas and proposes a new classification of gastric cancers into 4 subtypes, which should help with clinical assessment and trials of targeted therapies. This contribution from The Cancer Genome Atlas (TCGA) project describes the molecular evaluation of 295 primary gastric adenocarcinomas. Based on the results, the authors propose a novel classification separating gastric cancers into four subtypes according to: Epstein–Barr virus positive status, microsatellite instability, chromosomal instability or genomic stability. Given the histologic and etiologic heterogeneity of gastric cancer identification of these subtypes, using a schema that can readily be applied to patient samples should help with patient stratification and trials of targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many of the miRNAs were also reported by a recent systems biology paper from TCGA in 2014 [34].”
From Bioinformatic Interrogation of 5p-arm and 3p-arm Specific miRNA Expression Using TCGA Datasets (2015) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The fusion of this evidence has prompted TCGA and the Asian Cancer Research Group (ACRG) to propose several molecular classifications [77,78].”
From Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer (2024) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“The TP53/APC double knockout (DKO) organoid line was established in our previous studies by sequentially disrupting TP53 and APC37, two common oncogenic loci in gastric adenocarcinoma38,39, from non-neoplastic human gastric organoids (Fig. S1A).”
From Large-scale CRISPR screening in primary human 3D gastric organoids enables comprehensive dissection of gene-drug interactions (2025) · cites this paper as [38]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Fusobacterium spp. is important in the development and progression of gastrointestinal tumors1,19,34,35”
From RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach (2020) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Self-citationLAURÉN, P. (1965) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/apm.1965.64.1.31 · Cited by 6,133
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationWHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Cell Migration: Integrating Signals from Front to Back
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T., & Horwitz, A. R. (2003) · Science · doi:10.1126/science.1092053 · Cited by 4,978
Helicobacter pylori Infection and the Development of Gastric Cancer
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., & Schlemper, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa001999 · Cited by 4,465
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Research works printed but not linked: 2
- Ferlay, J. et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. IARC CancerBase 11, http://globocan.iarc.fr, accessed on January 15, 2014 (2013)
- The Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012) · DOI · Paper page
Cited by
Items 201–300 of 1,024
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Corvera, C. U., Das, P., Enzinger, P. C., Enzler, T., Gerdes, H., Gibson, M. K., Grierson, P., et al. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.0022 · Cited by 215
Comprehensive assessment of cancer missense mutation clustering in protein structures
Kamburov, A., Lawrence, M. S., Polak, P., Leshchiner, I., Lage, K., Golub, T. R., Lander, E. S., & Getz, G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516373112 · Cited by 225
Kawazoe, A., Kuwata, T., Kuboki, Y., Shitara, K., Nagatsuma, A. K., Aizawa, M., Yoshino, T., Doi, T., Ohtsu, A., & Ochiai, A. (2017) · Gastric Cancer · doi:10.1007/s10120-016-0631-3 · Cited by 225
Luo, Y., Zheng, S., Wu, Q., Wu, J., Zhou, R., Wang, C., Wu, Z., Rong, X., Huang, N., Sun, L., et al. (2021) · Autophagy · doi:10.1080/15548627.2021.1901204 · Cited by 222
Telonis, A. G., Magee, R., Loher, P., Chervoneva, I., Londin, E., & Rigoutsos, I. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx082 · Cited by 224
Ratti, M., Lampis, A., Hahne, J. C., Passalacqua, R., & Valeri, N. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2906-9 · Cited by 223
The NF1 gene in tumor syndromes and melanoma
Kiuru, M., & Busam, K. J. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2016.142 · Cited by 217
Current status of immune checkpoint inhibitors for gastric cancer
Kono, K., Nakajima, S., & Mimura, K. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01090-4 · Cited by 220
A novel gene expression-based prognostic scoring system to predict survival in gastric cancer
Wang, P., Wang, Y., Hang, B., Zou, X., & Mao, J.-H. (2016) · Oncotarget · doi:10.18632/oncotarget.10533 · Cited by 220
Cheong, J.-H., Yang, H.-K., Kim, H., Kim, W. H., Kim, Y.-W., Kook, M.-C., Park, Y.-K., Kim, H.-H., Lee, H. S., Lee, K. H., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30108-6 · Cited by 219
Self-citationClaudin 18.2 as a novel therapeutic target
Nakayama, I., Qi, C., Chen, Y., Nakamura, Y., Shen, L., & Shitara, K. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00874-2 · Cited by 210
“Limited data are available on the prevalence of claudin 18.2 expression in other TCGA gastric cancer subtypes, although an IHC analysis demonstrated claudin 18.2 expression in 20.8% of mismatch repair-deficient (dMMR) cancers.”
InfluentialTada, Y., Togashi, Y., Kotani, D., Kuwata, T., Sato, E., Kawazoe, A., Doi, T., Wada, H., Nishikawa, H., & Shitara, K. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0403-1 · Cited by 214
“TP53 were frequently mutated (10/17) and ERBB2, MET, FGFR2, or KRAS, amplification, or a RHOA mutation were also identified, which was in line with a previous study [25].”
ResultGrady, W. M., Yu, M., & Markowitz, S. D. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.09.058 · Cited by 214
Muro, K., Van Cutsem, E., Narita, Y., Pentheroudakis, G., Baba, E., Li, J., Ryu, M. H., Zamaniah, W. I. W., Yong, W. P., Yeh, K. H., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy502 · Cited by 213
Update on Metastatic Gastric and Esophageal Cancers
Shah, M. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.1799 · Cited by 213
Best practices for bioinformatic characterization of neoantigens for clinical utility
Richters, M. M., Xia, H., Campbell, K. M., Gillanders, W. E., Griffith, O. L., & Griffith, M. (2019) · Genome Medicine · doi:10.1186/s13073-019-0666-2 · Cited by 214
Gender medicine and oncology: report and consensus of an ESMO workshop
Wagner, A. D., Oertelt-Prigione, S., Adjei, A., Buclin, T., Cristina, V., Csajka, C., Coukos, G., Dafni, U., Dotto, G.-P., Ducreux, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz414 · Cited by 214
Becht, E., Giraldo, N. A., Germain, C., de Reyniès, A., Laurent-Puig, P., Zucman-Rossi, J., Dieu-Nosjean, M.-C., Sautès-Fridman, C., & Fridman, W. H. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2015.12.002 · Cited by 213
A Selective Review of Multi-Level Omics Data Integration Using Variable Selection
Wu, C., Zhou, F., Ren, J., Li, X., Jiang, Y., & Ma, S. (2019) · High-Throughput · doi:10.3390/ht8010004 · Cited by 213
Microsatellite instability in Gastric Cancer: Between lights and shadows
Puliga, E., Corso, S., Pietrantonio, F., & Giordano, S. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102175 · Cited by 209
Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer
Zeng, Y., & Jin, R. U. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.12.004 · Cited by 209
CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer
Leiserson, M. D., Wu, H.-T., Vandin, F., & Raphael, B. J. (2015) · Genome Biology · doi:10.1186/s13059-015-0700-7 · Cited by 210
Gastric Cancer as Preventable Disease
Rugge, M., Genta, R. M., Di Mario, F., El-Omar, E. M., El-Serag, H. B., Fassan, M., Hunt, R. H., Kuipers, E. J., Malfertheiner, P., Sugano, K., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.05.023 · Cited by 209
Molecular genetics and targeted therapy of WNT-related human diseases (Review)
Katoh, M., & Katoh, M. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3071 · Cited by 207
“…mutations, gain-of-function CTNNB1 mutations or loss-of-function RNF43 or ZNRF3 mutations have also been reported in breast cancer (33), gastric cancer (34), hepatocellular carcinoma (35), lung cancer (36), pancreatic cancer (37), prostate cancer (38) and uterine corpus endometrial carcinoma (39).”
BackgroundImmune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Panda, A., Mehnert, J. M., Hirshfield, K. M., Riedlinger, G., Damare, S., Saunders, T., Kane, M., Sokol, L., Stein, M. N., Poplin, E., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx213 · Cited by 208
Epstein–Barr virus-associated gastric cancer: A distinct subtype
Yang, J., Liu, Z., Zeng, B., Hu, G., & Gan, R. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.019 · Cited by 206
Noorbakhsh, J., Farahmand, S., Foroughi pour, A., Namburi, S., Caruana, D., Rimm, D., Soltanieh-ha, M., Zarringhalam, K., & Chuang, J. H. (2020) · Nature Communications · doi:10.1038/s41467-020-20030-5 · Cited by 206
Microsatellite instability: an update
Yamamoto, H., & Imai, K. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1474-0 · Cited by 247
TGF-β Signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer
Gough, N. R., Xiang, X., & Mishra, L. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.064 · Cited by 202
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Katoh, M., Loriot, Y., Brandi, G., Tavolari, S., Wainberg, Z. A., & Katoh, M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00869-z · Cited by 195
“By contrast, concurrent TP53 mutations are frequent in many other cancer types, especially intestinal-type gastric cancers harbouring FGFR2 , EGFR , ERBB2 , MET , KRAS or PIK3CA amplifications 137 , including TP53 driver alterations in 28 of 57 (49”
How to stomach an epigenetic insult: the gastric cancer epigenome
Padmanabhan, N., Ushijima, T., & Tan, P. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.53 · Cited by 202
Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy
Lee, J.-K., Liu, Z., Sa, J. K., Shin, S., Wang, J., Bordyuh, M., Cho, H. J., Elliott, O., Chu, T., Choi, S. W., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0209-6 · Cited by 203
New clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B.-D., Jiao, X.-D., Liu, K., Wang, Z., & Zang, Y.-S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 197
“332 Unfortunately, the treatment-guided value of these molecular pro fi ling types remains uncertain owing to the lack of adequate clinical data.”
BackgroundYang, J., Gong, Y., Lam, V. K., Shi, Y., Guan, Y., Zhang, Y., Ji, L., Chen, Y., Zhao, Y., Qian, F., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2531-z · Cited by 200
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer
Al-Ahmadie, H. A., Iyer, G., Lee, B. H., Scott, S. N., Mehra, R., Bagrodia, A., Jordan, E. J., Gao, S. P., Ramirez, R., Cha, E. K., et al. (2016) · Nature Genetics · doi:10.1038/ng.3503 · Cited by 200
Mast Cells, Angiogenesis and Lymphangiogenesis in Human Gastric Cancer
Sammarco, G., Varricchi, G., Ferraro, V., Ammendola, M., De Fazio, M., Altomare, D. F., Luposella, M., Maltese, L., Currò, G., Marone, G., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092106 · Cited by 198
Epstein‐Barr virus strain variation and cancer
Kanda, T., Yajima, M., & Ikuta, K. (2019) · Cancer Science · doi:10.1111/cas.13954 · Cited by 197
The JAK/STAT3 axis: A comprehensive drug target for solid malignancies
Huynh, J., Etemadi, N., Hollande, F., Ernst, M., & Buchert, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.06.001 · Cited by 198
Ye, G., Yang, Q., Lei, X., Zhu, X., Li, F., He, J., Chen, H., Ling, R., Zhang, H., Lin, T., et al. (2020) · Theranostics · doi:10.7150/thno.46001 · Cited by 197
“Wnt/β-catenin, proliferation/stem cell, Hippo and NF-κB pathways) [7-9].”
MEF2 transcription factors: developmental regulators and emerging cancer genes
Pon, J. R., & Marra, M. A. (2016) · Oncotarget · doi:10.18632/oncotarget.6223 · Cited by 196
Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer
Wang, D.-S., Liu, Z.-X., Lu, Y.-X., Bao, H., Wu, X., Zeng, Z.-L., Liu, Z., Zhao, Q., He, C.-Y., Lu, J.-H., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316522 · Cited by 195
Deregulation of Rho GTPases in cancer
Porter, A. P., Papaioannou, A., & Malliri, A. (2016) · Small GTPases · doi:10.1080/21541248.2016.1173767 · Cited by 194
Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer
Li, X., Pasche, B., Zhang, W., & Chen, K. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2805 · Cited by 195
Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition
Jia, D., Augert, A., Kim, D.-W., Eastwood, E., Wu, N., Ibrahim, A. H., Kim, K.-B., Dunn, C. T., Pillai, S. P. S., Gazdar, A. F., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0385 · Cited by 192
Organoid models of gastrointestinal cancers in basic and translational research
Lau, H. C. H., Kranenburg, O., Xiao, H., & Yu, J. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0255-2 · Cited by 194
Wang, J., Ge, J., Wang, Y., Xiong, F., Guo, J., Jiang, X., Zhang, L., Deng, X., Gong, Z., Zhang, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28479-2 · Cited by 195
The immune microenvironment in gastric adenocarcinoma
Zavros, Y., & Merchant, J. L. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00591-0 · Cited by 188
Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression
Wang, R., Song, S., Qin, J., Yoshimura, K., Peng, F., Chu, Y., Li, Y., Fan, Y., Jin, J., Dang, M., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.005 · Cited by 187
Hou, Y., Wu, K., Shi, X., Li, F., Song, L., Wu, H., Dean, M., Li, G., Tsang, S., Jiang, R., et al. (2015) · Gigascience · doi:10.1186/s13742-015-0068-3 · Cited by 191
The genomic landscape of schwannoma
Agnihotri, S., Jalali, S., Wilson, M. R., Danesh, A., Li, M., Klironomos, G., Krieger, J. R., Mansouri, A., Khan, O., Mamatjan, Y., et al. (2016) · Nature Genetics · doi:10.1038/ng.3688 · Cited by 189
Wong, S. S., Kim, K.-M., Ting, J. C., Yu, K., Fu, J., Liu, S., Cristescu, R., Nebozhyn, M., Gong, L., Yue, Y. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6477 · Cited by 190
The molecular origin and taxonomy of mucinous ovarian carcinoma
Cheasley, D., Wakefield, M. J., Ryland, G. L., Allan, P. E., Alsop, K., Amarasinghe, K. C., Ananda, S., Anglesio, M. S., Au-Yeung, G., Böhm, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11862-x · Cited by 191
PDXNET Consortium, Woo, X. Y., EurOPDX Consortium, Giordano, J., Srivastava, A., Zhao, Z.-M., Lloyd, M. W., de Bruijn, R., Suh, Y.-S., Patidar, R., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00750-6 · Cited by 190
Self-citationThe next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment
Rodriguez, H., Zenklusen, J. C., Staudt, L. M., Doroshow, J. H., & Lowy, D. R. (2021) · Cell · doi:10.1016/j.cell.2021.02.055 · Cited by 189
Targeting ARID1A mutations in cancer
Mullen, J., Kato, S., Sicklick, J. K., & Kurzrock, R. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102287 · Cited by 186
Gastric Cancer: Advances in Carcinogenesis Research and New Therapeutic Strategies
Seeneevassen, L., Bessède, E., Mégraud, F., Lehours, P., Dubus, P., & Varon, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073418 · Cited by 185
Predictive biomarkers in gastric cancer
Röcken, C. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04408-0 · Cited by 186
Salem, M. E., Puccini, A., Xiu, J., Raghavan, D., Lenz, H.-J., Korn, W. M., Shields, A. F., Philip, P. A., Marshall, J. L., & Goldberg, R. M. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0143 · Cited by 185
A mutational signature in gastric cancer suggests therapeutic strategies
Alexandrov, L. B., Nik-Zainal, S., Siu, H. C., Leung, S. Y., & Stratton, M. R. (2015) · Nature Communications · doi:10.1038/ncomms9683 · Cited by 185
Jiang, Y., Chen, C., Xie, J., Wang, W., Zha, X., Lv, W., Chen, H., Hu, Y., Li, T., Yu, J., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.007 · Cited by 184
Gastric Cancer Etiology and Management in Asia and the West
Russo, A. E., & Strong, V. E. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-081117-043436 · Cited by 181
A body map of somatic mutagenesis in morphologically normal human tissues
Li, R., Di, L., Li, J., Fan, W., Liu, Y., Guo, W., Liu, W., Liu, L., Li, Q., Chen, L., et al. (2021) · Nature · doi:10.1038/s41586-021-03836-1 · Cited by 183
Self-citationApplications of organoids for cancer biology and precision medicine
Lo, Y.-H., Karlsson, K., & Kuo, C. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0102-y · Cited by 182
Zheng, H., Dai, W., Cheung, A. K. L., Ko, J. M. Y., Kan, R., Wong, B. W. Y., Leong, M. M. L., Deng, M., Kwok, T. C. T., Chan, J. Y.-W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607606113 · Cited by 182
Ghaffari Laleh, N., Muti, H. S., Loeffler, C. M. L., Echle, A., Saldanha, O. L., Mahmood, F., Lu, M. Y., Trautwein, C., Langer, R., Dislich, B., et al. (2022) · Medical Image Analysis · doi:10.1016/j.media.2022.102474 · Cited by 179
Izumi, D., Ishimoto, T., Miyake, K., Sugihara, H., Eto, K., Sawayama, H., Yasuda, T., Kiyozumi, Y., Kaida, T., Kurashige, J., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.29864 · Cited by 181
Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell
Gao, J.-P., Xu, W., Liu, W.-T., Yan, M., & Zhu, Z.-G. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i24.2567 · Cited by 181
Liu, X., Wu, J., Zhang, D., Bing, Z., Tian, J., Ni, M., Zhang, X., Meng, Z., & Liu, S. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00265 · Cited by 180
“In recent years, the advancement of microarray and high throughput sequencing technologies has provided an efficient tool to decipher critical genetic or epigenetic alternations in carcinogenesis and to discover promising biomarkers for cancer diagnosis, treatment and prognosis (Kulasingam and Diamandis, 2008; Cancer…”
BackgroundPan, K.-F., Zhang, L., Gerhard, M., Ma, J.-L., Liu, W.-D., Ulm, K., Wang, J.-X., Zhang, L., Zhang, Y., Bajbouj, M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309197 · Cited by 180
Epigenetic inactivation of the p53-induced long noncoding RNA TP53 target 1 in human cancer
Diaz-Lagares, A., Crujeiras, A. B., Lopez-Serra, P., Soler, M., Setien, F., Goyal, A., Sandoval, J., Hashimoto, Y., Martinez-Cardús, A., Gomez, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608585113 · Cited by 180
Medical management of gastric cancer: a 2017 update
Charalampakis, N., Economopoulou, P., Kotsantis, I., Tolia, M., Schizas, D., Liakakos, T., Elimova, E., Ajani, J. A., & Psyrri, A. (2018) · Cancer Medicine · doi:10.1002/cam4.1274 · Cited by 179
Zhao, L., Han, T., Li, Y., Sun, J., Zhang, S., Liu, Y., Shan, B., Zheng, D., & Shi, J. (2017) · The FASEB Journal · doi:10.1096/fj.201600994r · Cited by 179
Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases
Cui, X., & Snapper, C. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.734471 · Cited by 177
Nasopharyngeal Cancer: Molecular Landscape
Bruce, J. P., Yip, K., Bratman, S. V., Ito, E., & Liu, F.-F. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.7846 · Cited by 178
Kim, R., An, M., Lee, H., Mehta, A., Heo, Y. J., Kim, K.-M., Lee, S.-Y., Moon, J., Kim, S. T., Min, B.-H., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0888 · Cited by 174
“According to The Cancer Genome Atlas (TCGA) classifications, three patients had genomically stable (GS) tumors, whereas the remaining nine patients were chromosomally instable (20).”
Pan-cancer patterns of DNA methylation
Witte, T., Plass, C., & Gerhauser, C. (2014) · Genome Medicine · doi:10.1186/s13073-014-0066-6 · Cited by 175
Next generation sequencing‐based gene panel tests for the management of solid tumors
Nagahashi, M., Shimada, Y., Ichikawa, H., Kameyama, H., Takabe, K., Okuda, S., & Wakai, T. (2019) · Cancer Science · doi:10.1111/cas.13837 · Cited by 177
Huang, T., Song, C., Zheng, L., Xia, L., Li, Y., & Zhou, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0967-5 · Cited by 177
Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes
Gullo, I., Grillo, F., Mastracci, L., Vanoli, A., Carneiro, F., Saragoni, L., Limarzi, F., Ferro, J., Parente, P., & Fassan, M. (2020) · Pathologica · doi:10.32074/1591-951x-166 · Cited by 177
Kubota, Y., Kawazoe, A., Mishima, S., Nakamura, Y., Kotani, D., Kuboki, Y., Bando, H., Kojima, T., Doi, T., Yoshino, T., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2022.100762 · Cited by 174
Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy
Chen, K., Yang, D., Li, X., Sun, B., Song, F., Cao, W., Brat, D. J., Gao, Z., Li, H., Liang, H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422640112 · Cited by 175
AGA technical review on gastric intestinal metaplasia-natural history and clinical outcomes
Gawron, A. J., Shah, S. C., Altayar, O., Davitkov, P., Morgan, D., Turner, K., & Mustafa, R. A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.001 · Cited by 175
The importance of regulatory ubiquitination in cancer and metastasis
Gallo, L. H., Ko, J., & Donoghue, D. J. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1288326 · Cited by 175
Lee, S., Park, H. Y., Kang, S. Y., Kim, S. J., Hwang, J., Lee, S., Kwak, S. H., Park, K. S., Yoo, H. Y., Kim, W. S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3776 · Cited by 174
Eso, Y., Shimizu, T., Takeda, H., Takai, A., & Marusawa, H. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-019-01620-7 · Cited by 174
Lo, Y.-H., Kolahi, K. S., Du, Y., Chang, C.-Y., Krokhotin, A., Nair, A., Sobba, W. D., Karlsson, K., Jones, S. J., Longacre, T. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1109 · Cited by 174
Self-citationMicrobial carcinogenesis: Lactic acid bacteria in gastric cancer
Vinasco, K., Mitchell, H. M., Kaakoush, N. O., & Castaño-Rodríguez, N. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.07.004 · Cited by 171
Protein neddylation and its role in health and diseases
Zhang, S., Yu, Q., Li, Z., Zhao, Y., & Sun, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01800-9 · Cited by 171
Self-citationInhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance
Shahar, N., & Larisch, S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100712 · Cited by 165
Mapping the genomic diaspora of gastric cancer
Yeoh, K. G., & Tan, P. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00412-7 · Cited by 169
Kwak, E. L., Ahronian, L. G., Siravegna, G., Mussolin, B., Borger, D. R., Godfrey, J. T., Jessop, N. A., Clark, J. W., Blaszkowsky, L. S., Ryan, D. P., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0748 · Cited by 169
Immunotherapy in Gastric Cancer
Högner, A., & Moehler, M. (2022) · Current Oncology · doi:10.3390/curroncol29030131 · Cited by 168
Choi, E., Hendley, A. M., Bailey, J. M., Leach, S. D., & Goldenring, J. R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.11.049 · Cited by 166
Zhang, H., Li, R., Cao, Y., Gu, Y., Lin, C., Liu, X., Lv, K., He, X., Fang, H., Jin, K., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000004037 · Cited by 168
Rho GTPases in cancer: friend or foe?
Svensmark, J. H., & Brakebusch, C. (2019) · Oncogene · doi:10.1038/s41388-019-0963-7 · Cited by 165
Zhang, H., Schaefer, A., Wang, Y., Hodge, R. G., Blake, D. R., Diehl, J. N., Papageorge, A. G., Stachler, M. D., Liao, J., Zhou, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0811 · Cited by 164
Rihawi, K., Ricci, A. D., Rizzo, A., Brocchi, S., Marasco, G., Pastore, L. V., Llimpe, F. L. R., Golfieri, R., & Renzulli, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083805 · Cited by 166
Early-Onset Cancer in the Gastrointestinal Tract Is on the Rise—Evidence and Implications
Ben-Aharon, I., van Laarhoven, H. W. M., Fontana, E., Obermannova, R., Nilsson, M., & Lordick, F. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1038 · Cited by 166
Large-scale profiling of microRNAs for The Cancer Genome Atlas
Chu, A., Robertson, G., Brooks, D., Mungall, A. J., Birol, I., Coope, R., Ma, Y., Jones, S., & Marra, M. A. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv808 · Cited by 165
Analysis of Racial/Ethnic Representation in Select Basic and Applied Cancer Research Studies
Guerrero, S., López-Cortés, A., Indacochea, A., García-Cárdenas, J. M., Zambrano, A. K., Cabrera-Andrade, A., Guevara-Ramírez, P., González, D. A., Leone, P. E., & Paz-y-Miño, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-32264-x · Cited by 163
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2014-07-23
- Volume
- 513
- Issue
- 7517
- Pages
- 202-209
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4170219
- OpenAlex
- W2126547130
- Cited by
- 6,498
- References
- 43
- Citations by year
- 2026: 455 · 2025: 481 · 2024: 569 · 2023: 637 · 2022: 620 · 2021: 737 · 2020: 653 · 2019: 554 · 2018: 560 · 2017: 490 · 2016: 398 · 2015: 297 · 2014: 41
- FWCI
- 327.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- KUMeL Repository (Keimyung University) (submittedVersion, cc-by-nc-nd)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, R01HG007069, U54HG003079, U54HG003273, R01HG005690)
- National Cancer Institute (P30CA16672, K08CA134931, P50CA098258, U24CA143882, P01CA028842, R01CA180006, U24CA143843, U24CA143840, U24CA143858, U24CA126543, U24CA144025, U24CA143866, U24CA143883, U24CA143845, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA143835, K99CA166729, P30CA008748, P30CA016672, P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Keywords
- gastric adenocarcinoma, molecular classification, Epstein-Barr virus, PIK3CA mutation, DNA hypermethylation, PD-L1, PD-L2, microsatellite instability, chromosomal instability, genome stability, RHOA mutations, aneuploidy, targeted therapy, patient stratification
- MeSH terms
- Adenocarcinoma, Herpesvirus 4, Human, Female, Humans, Male, Mutation, Stomach Neoplasms, Genome, Human, Gene Expression Regulation, Neoplastic, Proteome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.